Neulasta Onpro is a wearable, on-body injection system that automatically delivers a dose of pegfilgrastim, a medication that boosts white blood cell production after chemotherapy. Instead of returning to the clinic the day after treatment for a separate injection, you wear a small adhesive device home from your chemotherapy appointment. It delivers your full 6 mg dose approximately 27 hours later, timed to align with when your body needs it most.
What the Device Does and Why It Matters
Chemotherapy attacks fast-growing cells, which includes cancer cells but also the white blood cells your immune system depends on. When white blood cell counts drop dangerously low, a condition called neutropenia, even a minor infection can become life-threatening. Febrile neutropenia, where a patient develops a fever during this vulnerable window, is one of the most serious short-term risks of chemotherapy.
Pegfilgrastim, the medication inside the Onpro device, stimulates your bone marrow to produce more neutrophils, the white blood cells that fight bacterial infections. In a pivotal trial of 928 breast cancer patients receiving chemotherapy, only 1% of those given pegfilgrastim developed febrile neutropenia compared to 17% of those given a placebo. Hospitalizations dropped from 14% to 1%, and the need for intravenous antibiotics fell from 10% to 2%.
How the Onpro Kit Works
The kit has two main parts: a prefilled syringe containing the pegfilgrastim and the on-body injector itself. During your chemotherapy visit, a healthcare provider loads the prefilled syringe into the small injector device and applies it to the back of your arm or your abdomen using its adhesive backing. The device is about the size of a small egg and sticks to your skin like a large bandage.
Once applied, the device begins an internal countdown. Roughly 27 hours later, it automatically inserts a small needle, delivers the medication under your skin over about 45 minutes, and then retracts the needle. The device has a status indicator so you can confirm whether the medication has been delivered. After the injection is complete, you peel the device off and dispose of it in a sharps container.
What You’ll Feel While Wearing It
The device is lightweight enough that most people can sleep, shower (with precautions to keep it dry), and go about normal activities while wearing it. You’ll hear a click or beep when the injection process begins, and you may feel a brief pinch as the needle inserts. The injection itself is slow enough that most patients describe it as mild pressure rather than pain.
About 5% of patients in one study reported the device detaching before completing the injection. If that happens, or if you notice any sign that the dose wasn’t fully delivered, you should contact your oncology team. They may need to arrange a backup injection.
The Convenience Factor
Before Onpro existed, patients had to return to the clinic the day after each chemotherapy cycle for a manual pegfilgrastim injection. For many people already exhausted from treatment, that extra trip was a real burden, especially those who live far from their cancer center or rely on others for transportation. The on-body injector eliminates that return visit entirely while delivering the same clinical benefit. Studies comparing the two delivery methods found equivalent effectiveness at preventing febrile neutropenia.
Bone Pain and Other Side Effects
Bone pain is the most notable side effect directly tied to pegfilgrastim, regardless of how it’s delivered. It occurs because the drug is pushing your bone marrow into overdrive to produce white blood cells. In clinical trials, about 26% of pegfilgrastim patients experienced bone pain that investigators attributed to the drug, most commonly in the back, limbs, and skeleton generally. Severe bone pain occurred in roughly 3% to 6% of patients depending on the dose.
Most of the other side effects patients report, such as nausea (72%), fatigue (70%), hair loss (69%), and diarrhea (49%), overlap heavily with effects of the chemotherapy itself rather than the pegfilgrastim. In head-to-head comparisons with an older, daily-injection version of the same type of drug, pegfilgrastim actually showed slightly lower rates of treatment-related side effects overall: 38% versus 47%.
Some patients also experience mild skin irritation or redness at the adhesive site, which is specific to the on-body injector rather than the medication.
Who Gets Neulasta Onpro
The standard adult dose is a single 6 mg injection once per chemotherapy cycle. It’s prescribed for patients receiving chemotherapy regimens that carry a significant risk of suppressing the immune system. Not every chemotherapy protocol warrants it. Your oncologist will assess the risk based on the specific drugs in your regimen, the dose intensity, and your individual health factors.
Children weighing less than 45 kg receive weight-based dosing through a standard syringe rather than the on-body injector, since the device delivers a fixed 6 mg dose that can’t be adjusted downward. Children 45 kg and above receive the same adult dose.
Biosimilars and Availability
Pegfilgrastim has been available since the early 2000s, and several biosimilar versions now exist. These are near-identical copies approved by the FDA with the same dosing, effectiveness, and safety profile. If your insurance plan steers you toward a biosimilar, the medication works the same way, though not all biosimilars offer an on-body injector option. If avoiding that extra clinic visit matters to you, it’s worth asking your care team whether the on-body delivery format is available with whatever version your plan covers.